Weight-Loss Drug Candidate Cuts Liver Fat in Trial
Adults with obesity and fatty liver may one day have an option that targets both, though current results come from a small early-stage study.
Updated on Nov. 5, 2026 in Weight Loss

MetaVia reported phase 1 trial results for DA-1726, an investigational once-weekly GLP-1/glucagon receptor agonist, showing reductions in liver fat and body weight in adults with obesity. The data come from part of a small study of 15 adults, with the company planning a phase 2 trial in alcohol-associated liver disease.
Why it matters
Liver fat accumulation is a common feature of obesity, and an agent that reduces it alongside weight could widen treatment options for people with both conditions. MetaVia's results are early, so they offer a rationale for further testing rather than evidence of an established therapy.
The data come from a phase 1 study of 15 otherwise healthy adults with obesity, with four participants receiving placebo, dosed once weekly for 16 weeks. Results showed a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted body weight loss, and no participant discontinued because of a gastrointestinal adverse event.
The players
MetaVia
MetaVia is a biopharmaceutical company developing DA-1726 for obesity and liver disease.
Altimmune
Altimmune is a biopharmaceutical company developing pemvidutide, a GLP-1/glucagon receptor agonist, including in alcohol-associated liver disease.
The details
DA-1726 is a GLP-1/glucagon receptor agonist, a class of drug that targets two hormone pathways involved in appetite, blood sugar and energy use. Given once weekly, it was tested in a small early-stage study. Five participants with liver steatosis, or fatty liver, showed improvements, which is the basis for MetaVia's interest in extending the drug into liver disease.
Timeline
Phase 1 dosing ran once weekly for 16 weeks.
MetaVia plans to start a phase 2 trial of DA-1726 in alcohol-associated liver disease in 2027.
MetaVia aims to begin a 48-week, non-biopsy phase 2 study in up to 150 subjects with ALD in the second half of 2027.
Health Landscape
Dual GLP-1/glucagon agonists are being tested as both weight-loss and liver-disease treatments, with Altimmune's pemvidutide pursuing alcohol-associated liver disease in the same timeframe. MetaVia's early data add a second candidate to that pipeline, though neither program has reported late-stage results.
If you have obesity and fatty liver, this early research suggests a dual-action approach may someday address both, but it is years from clinical use. Anyone with liver or weight concerns should discuss current options and monitoring with their physician.
The takeaway
Early data suggest a once-weekly drug may reduce liver fat and body weight together, but results come from a very small phase 1 study. Anyone managing obesity or fatty liver should ask their doctor which evidence-based options fit their situation.
What happens next
MetaVia plans to start a 48-week phase 2 study in up to 150 people with alcohol-associated liver disease in the second half of 2027, and Altimmune expects top-line pemvidutide data in the same period.
Further reading
Explore related coverage in our Weight Loss section.


